Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Patients with insulin resistance often manifest increased intramyocellular lipid (IMCL) along with increased visceral adipose tissue. This study was designed to determine whether the insulin sensitizer drugs pioglitazone and metformin would improve glucose intolerance and insulin sensitivity by decreasing IMCL. In this study, 23 generally healthy subjects with impaired glucose tolerance were randomized to receive either pioglitazone 45 mg/day or metformin 2,000 mg/day for 10 wk. Before and after treatment, we measured insulin sensitivity and abdominal subcutaneous and visceral adipose tissue with CT scanning. In addition, muscle biopsies were performed for measurement of IMCL and muscle oxidative enzymes. After treatment with pioglitazone, 2-h glucose fell from 9.6 mmol/l (172 mg/dl) to 6.1 mmol/l (119 mg/dl), whereas there was no change in 2-h glucose with metformin. With pioglitazone treatment, there was a 65% increase in insulin sensitivity along with a 34% decrease in IMCL (both P ≤ 0.002). This decrease in IMCL was not due to increased muscle lipid oxidation, as there were no changes in muscle lipid oxidative enzymes. However, pioglitazone resulted in a 2.6-kg weight gain along with a significant decrease in the visceral-to-subcutaneous adipose tissue ratio. In contrast, metformin treatment resulted in no change in insulin sensitivity, IMCL, oxidative enzymes, or adipose tissue volumes. Pioglitazone improved glucose tolerance and insulin sensitivity by reducing IMCL. This reduction in IMCL was not due to an increase in muscle lipid oxidation but to a diversion of lipid from ectopic sites into subcutaneous adipose tissue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes
Petersen, K. F., Dufour, S., Befroy, D., Garcia, R., & Shulman, G. I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031314 · Cited by 2,193
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053
Quantitative estimation of insulin sensitivity.
Bergman, R. N., Ider, Y. Z., Bowden, C. R., & Cobelli, C. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.236.6.e667 · Cited by 1,874
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247
Perseghin, G., Scifo, P., De Cobelli, F., Pagliato, E., Battezzati, A., Arcelloni, C., Vanzulli, A., Testolin, G., Pozza, G., Del Maschio, A., et al. (1999) · Diabetes · doi:10.2337/diabetes.48.8.1600 · Cited by 877
Cited by
Adipocytokines and the Metabolic Complications of Obesity
Rasouli, N., & Kern, P. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1613 · Cited by 743
Self-citationSharma, A. M., & Staels, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1268 · Cited by 479
AMPK inhibition in health and disease
Viollet, B., Horman, S., Leclerc, J., Lantier, L., Foretz, M., Billaud, M., Giri, S., & Andreelli, F. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2010.488215 · Cited by 383
OXPAT/PAT-1 Is a PPAR-Induced Lipid Droplet Protein That Promotes Fatty Acid Utilization
Wolins, N. E., Quaynor, B. K., Skinner, J. R., Tzekov, A., Croce, M. A., Gropler, M. C., Varma, V., Yao-Borengasser, A., Rasouli, N., Kern, P. A., et al. (2006) · Diabetes · doi:10.2337/db06-0399 · Cited by 327
Self-citationMetabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Hyperglycemia Predicts Persistently Lower Muscle Strength With Aging
Kalyani, R. R., Metter, E. J., Egan, J., Golden, S. H., & Ferrucci, L. (2015) · Diabetes Care · doi:10.2337/dc14-1166 · Cited by 236
Walton, R. G., Dungan, C. M., Long, D. E., Tuggle, S. C., Kosmac, K., Peck, B. D., Bush, H. M., Villasante Tezanos, A. G., McGwin, G., Windham, S. T., et al. (2019) · Aging Cell · doi:10.1111/acel.13039 · Cited by 210
“Although studies in sedentary humans have shown either no effect (Rasouli et al., 2005) or decreased (Teranishi et al., 2007) intramyo‐ cellular lipid following metformin treatment, the increased metabolic demands during PRT may require increased mitochondrial complex I activity, and metformin may…”
BackgroundSelf-citationVarma, V., Yao-Borengasser, A., Bodles, A. M., Rasouli, N., Phanavanh, B., Nolen, G. T., Kern, E. M., Nagarajan, R., Spencer, H. J., Lee, M.-J., et al. (2008) · Diabetes · doi:10.2337/db07-0840 · Cited by 194
“As we described previously (33), treatment with pioglitazone (but not metformin) improved the Si from 2.”
BackgroundSelf-citationMehta, J. L., Rasouli, N., Sinha, A. K., & Molavi, B. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.12.008 · Cited by 168
Self-citationMicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation
Ying, W., Tseng, A., Chang, R. C.-A., Morin, A., Brehm, T., Triff, K., Nair, V., Zhuang, G., Song, H., Kanameni, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81656 · Cited by 144
Lee, H.-Y., Lee, J. S., Alves, T., Ladiges, W., Rabinovitch, P. S., Jurczak, M. J., Choi, C. S., Shulman, G. I., & Samuel, V. T. (2017) · Diabetes · doi:10.2337/db16-1334 · Cited by 66
Nadeau, K. J., Ehlers, L. B., Aguirre, L. E., Moore, R. L., Jew, K. N., Ortmeyer, H. K., Hansen, B. C., Reusch, J. E. B., & Draznin, B. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00543.2005 · Cited by 57
Shea, M. K., Nicklas, B. J., Marsh, A. P., Houston, D. K., Miller, G. D., Isom, S., Miller, M. E., Carr, J. J., Lyles, M. F., Harris, T. B., et al. (2011) · Obesity · doi:10.1038/oby.2010.327 · Cited by 49
“Although others have reported that pioglitazone treatment (45 mg/day) lowers intramyocellular lipid content (38,39); the thigh intermuscular fat volume and leg muscle attenuation did not change in the men and women receiving pioglitazone in our study.”
BackgroundYue, L., & Mazzone, T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808482200 · Cited by 49
Marsh, A. P., Kyla Shea, M., Vance Locke, R. M., Miller, M. E., Isom, S., Miller, G. D., Nicklas, B. J., Lyles, M. F., Carr, J. J., & Kritchevsky, S. B. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls258 · Cited by 36
“Interestingly, pioglitazone has also been shown to decrease intramyocellular lipid content in individuals with T2D (16,17).”
BackgroundAssessment of intramuscular triglycerides: contribution to metabolic abnormalities
Dubé, J., & Goodpaster, B. H. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000241664.38385.12 · Cited by 31
Attallah, H., Friedlander, A. L., Nino-Murcia, M., & Hoffman, A. R. (2007) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0020021 · Cited by 19
“The control groups received either a placebo [56], metformin [55], or diet and exercise [54].”
Background
Metadata
- Authors
- Rasouli, N., Raue, U., Miles, L. M., Lu, T., Di Gregorio, G. B., Elbein, S. C., & Kern, P. A.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2005-05
- Volume
- 288
- Issue
- 5
- Pages
- E930-E934
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2136387838
- Cited by
- 148
- References
- 19
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.